Dr. Sara Ward discusses the SECURE trial with co-host, Dr. Tracy Macaulay
0:00-1:08: Introduction
1:09-3:40: SECURE trial overview
3:41-7:55: History of polypill and overall trial considerations
7:56-11:36: Polypill formulation and titration
11:37-14:04: Antiplatelet therapy in SECURE discussion
14:05-18:06: Polypill use in the US
18:07-19:29: Final thoughts
19:30-20:00: Closing
References:
SECURE Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-977. doi:10.1056/NEJMoa2208275
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and riskfactors, 1990–2019: update from the GBD 2019 Study. J Am Coll Cardiol 2020; 76: 2982–3021.
Bansilal S, Castellano JM, Garrido E, et al. Assessing the impact of medication adherence onlong-term cardiovascular outcomes. J Am Coll Cardiol 2016;68:789-801.
KolandaiveluK, Leiden BB, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications.Eur Heart J 2014; 35:3267-76.
Ferket BS, Hunink MG, Khanji M, et al. Cost-effectiveness of the polypill versus risk assessment forprevention of cardiovascular disease. Heart 2017;103:483-491.
Munoz D, Uzoije P, Reynolds C, et al. Polypill for cardiovascular disease prevention in an underservedpopulation. New Eng J Med 2019;381:1114-23.
Macaulay T, Sheridan E, Ward S. Reconsidering the Polypill for management of cardiovascularrisk factors in underserved patietsion. Curr Cardiol Rep 2021; 23:19.
Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons withoutcardiovascular disease. N Engl J Med 2021; 384: 216–28.
Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondaryprevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet2019; 394:672–83.
Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons withoutcardiovascular disease. N Engl J Med 2016; 374: 2032–43.
Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results fromthe FOCUS project. J Am Coll Cardiol 2014;64:2071-82.
Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin forprimary prevention of cardiovascular disease: an individual participant data meta-analysis.Lancet2021;398:1133-46.
CardioScripts 